Literature DB >> 188332

Mechanisms contributing to myocardial accumulation of technetium-99m stannous pyrophosphate after coronary arterial occlusion.

R E Coleman, M S Klein, S A Ahmed, E S Weiss, W M Buchholz, B E Sobel.   

Abstract

The relation between the accumulation of pyrophosphate and technetium-99m in myocardium with reversible and irreversible ischmic injury was studied in dogs subjected to transitory or persistent coronary arterial occlusion. Among four dogs with coronary occlusion maintained for less than 20 minutes, none had either increased MB creatine kinase (CK) (the "myocardial" CK isoenzyme) activity serum or a positive 99mTc stannous pyrophosphate image. Seven dogs with coronary occlusion maintained for 30 or more minutes had elevated serum MB CK activity, and five of the seven had positive (abnormal) images. Thus, although false negative images may occur occasionally despite myocardial damage, both increased serum MB CK and abnormal images generally accompanied prolonged coronary occlusion. In contrast, ischemia without infarction was not associated with abnormal images. Both 99mTc and 32P labeled pyrophosphate were accumulated extensively and proportionally in myocardium from zones of infarction, and uptake of both tracers was comparable although modest in isolated mitochondria. Similar results were obtained after myocardial infarction in animals with induced profound leukopenia. Thus, phagocytosis of the radiopharmaceutical agent by leukocytes migrating into the infarct is not an essential mechanism accounting for uptake. These results indicate that abnormal images reflect uptake of pyrophosphate, associated with 99mTc, by irreversibly injured myocardium rather than leukocytic infiltration involved in the inflammatory response in the heart.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 188332     DOI: 10.1016/s0002-9149(77)80011-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues.

Authors:  L M Buja; A J Tofe; P V Kulkarni; A Mukherjee; R W Parkey; M D Francis; F J Bonte; J T Willerson
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  Technetium-99m stannous pyrophosphate scintigraphy in patients with calcification within the cardiac silhouette.

Authors:  R W Wald; L Sternberg; V F Huckell; H M Staniloff; D H Feiglin; J E Morch
Journal:  Br Heart J       Date:  1978-05

3.  Clinical evaluation of positive myocardial imaging.

Authors:  T I Hale; A Jucker
Journal:  Eur J Nucl Med       Date:  1984

4.  Evaluation of kidney grafts with 99mTc-methylene diphosphonate within 36 hours after transplantation: a marker of ischemic damage.

Authors:  H S Thomsen; H Løkkegaard; O Munck
Journal:  Eur J Nucl Med       Date:  1984

5.  Myocardial imaging.

Authors: 
Journal:  Br Med J       Date:  1978-09-09

6.  Positive myocardial scintigraphy at the bedside--evaluation using a portable gamma camera.

Authors:  D S Dymond; P H Jarritt; K E Britton; D Langley; R A Spurrell
Journal:  Postgrad Med J       Date:  1978-10       Impact factor: 2.401

Review 7.  Acute myocardial infarction: clinical application of technetium 99m stannous pyrophosphate infarct scintigraphy.

Authors:  J A Werner; E H Botvinick; D M Shames; W W Parmley
Journal:  West J Med       Date:  1977-12

8.  Localization of In-111 antimyosin Fab and 99mTc-pyrophosphate in reperfusion myocardial infarction model.

Authors:  D S Lee; M C Lee; J K Chung; C S Koh; D H Moon
Journal:  Korean J Intern Med       Date:  1990-01       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.